Gradient Purple Blue

The ActivePure Technologies Advisory Board

The expertise and guidance of our advisors have enabled us to successfully proceed in the development of the fastest-acting, most powerful surface and air disinfecting purification technology available.

DR. DEBORAH BIRX

Chief Scientific and Medical Advisor
Gradient Purple Blue

Dr. Deborah Birx, Chief Scientific and Medical Advisor

Deborah L. Birx, MD is a world-renowned medical physician and expert on HIV/AIDS and infectious diseases and a diplomat who served as a special representative for global health diplomacy. Most recently, Birx served on the White House Coronavirus Task Force from Feb. 2020 to Jan. 2021. Her three-decade-long career has focused on HIV/AIDS immunology, vaccine research, and global health. As the U.S. Global AIDS Coordinator for presidents Barack Obama and Donald Trump, Birx oversaw the implementation of the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the largest commitment by any nation to combat a single disease in history, as well as all U.S. government engagement with the Global Fund to Fight AIDS, Tuberculosis, and Malaria. Serving as the U.S. Special Representative for Global Health Diplomacy, she aligned the U.S. Government’s diplomacy with foreign assistance programs that address global health challenges and accelerate progress toward achieving an AIDS-free generation; ending preventable child and maternal deaths; and preventing, detecting, and responding to infectious disease threats.

In 1985, Birx began her career with the Department of Defense (DoD) as a military-trained clinician in immunology, focusing on HIV/AIDS vaccine research. From 1985-1989 she served as an Assistant Chief of the Hospital Immunology Service at Walter Reed Army Medical Center. Through her professionalism and leadership in the field, she served as the Director of the U.S. Military HIV Research Program (USMHRP) at the Walter Reed Army Institute of Research from 1996-2005. Birx helped lead one of the most influential HIV vaccine trials in history (known as RV 144, or the Thai trial), which provided the first supporting evidence of any vaccine’s potential effectiveness in preventing HIV infection. During this time, she also rose to the rank of Colonel, bringing together the Navy, Army, and Air Force in a new model of cooperation – increasing the efficiency and effectiveness of the U.S. military’s HIV/AIDS efforts through inter-and intra-agency collaboration. Then known as Colonel Birx, she was awarded two prestigious U.S. Meritorious Service Medals and the Legion of Merit Award for her groundbreaking research, leadership and management skills during her tenure at DoD.

From 2005-2014, Birx served as the Director of the Centers for Disease Control and Prevention's (CDC) Division of Global HIV/AIDS (DGHA) in the CDC Center for Global Health. As DGHA Director, she utilized her leadership ability, superior technical skills, and passion to achieve tremendous health impact. She successfully led the implementation of CDC’s PEPFAR programs around the world and managed an annual budget of more than $1.5 billion. Birx was responsible for all of the agency's global HIV/AIDS activities, including providing oversight to more than 400 staff at headquarters, over 1,500 staff in the field, and more than 45 country and regional offices in Africa, Asia, the Caribbean, and Latin America. Recognized for her distinguished and dedicated commitment to building local capacity and strengthening quality laboratory health services and systems in Africa, in 2011, Birx received a Lifetime Achievement Award from the African Society for Laboratory Medicine. In 2014, CDC honored her leadership in advancing the agency’s HIV/AIDS response with the highly prestigious William C. Watson, Jr. Medal of Excellence, the highest honor bestowed by the CDC.

Birx received her medical degree from the Hershey School of Medicine, Pennsylvania State University. She trained in internal medicine and basic and clinical immunology at the Walter Reed Army Medical Center and the National Institutes of Health. Birx is board certified in internal medicine, allergy and immunology, and diagnostic and clinical laboratory immunology. She has published over 220 manuscripts in peer-reviewed journals, authored nearly a dozen chapters in scientific publications, as well as developed and patented vaccines.

Awards given to Dr. Birx

AP_Dr.BirxAwards_rev2.jpg
Gradient Purple Blue
JoeUrso_LettertothePresident2_nf.jpg

Dr. Birx recognizes that for America to reopen safely, another layer of protection is needed. She passionately believes that ActivePure is the solution to reopen American and get us back to work, to school, to restaurants, to events, to life before COVID-19.

Read ActivePure CEO and Chairman Joe Urso’s open letter to President Joe Biden on how we can help reopen American with this Amazing Technology.

Why Aren’t We Talking About Destroying COVID in Indoor Air?

An Open Letter on How to Open America

Dear President Biden:

Congratulations on your progress against COVID-19. Masks, testing, distancing, vaccines -- all are necessary. But not sufficient.

Any plan to bring America back must deploy technology that can eliminate SARS-CoV-2, the COVID virus, from interior air – safely and immediately.

As the recent letter from 13 public health experts to your COVID Coordinator, CDC Director, and Dr. Fauci warned, contaminated aerosols linger indoors, and action must be taken to limit transmission. “It’s time to stop pussyfooting around the fact that the virus is transmitted mostly through the air,” said Linsey Marr of Virginia Tech, one of the signers.1

The U.S. is the leader in the technology that can get this job done.

We developed technology, called ActivePure, that destroys the COVID virus in the air and have deployed it for decades. It’s unique, and it works.

By contrast, ventilation does not seek out the virus. Other systems are passive, slow, trap pathogens but don’t destroy them. Many are so dangerous, people can’t even be in the room. By contrast, our technology blasts out sub-microscopic particles that attack viruses and bacteria and destroy them in real time.2 Our system is safe for people and pets, and it works continuously.

It evolved from the NASA space program and is now used by hospitals, schools, offices, restaurants, and other businesses, and in hundreds of thousands of homes.

The technology works not just against SARS-CoV-2 but also against other deadly viruses and bacteria.3 Our FDA-cleared medical device is the subject of a double-blind trial being conducted by the Cleveland Clinic to test ActivePure’s effectiveness against surgical-site infections.4

In battling COVID, mutations are not an obstacle for this technology. It will bring Americans comfort and assurance now and after the pandemic ends.

Recent testing by an FDA-compliant, military-grade laboratory found more than 99.96% of airborne SARS-CoV-2 is eliminated in three minutes.5 Other U.S. companies may have similar solutions in the future, but spending billions on inferior systems now is wasteful.

Our technology is bringing millions of people back to the life they deserve.

Already, schools that use our technology are back in session – your goal. But every school in America should be benefiting from the science. So should meat-packing plants, grocery stores, health clinics, arenas and restaurants struggling to survive.

As more and more public health experts are recognizing, destroying COVID indoors is critical to ending the pandemic. I urge you and the nation’s governors and mayors to encourage – or, where you can, require -- the use of the best technology now.

It is the missing link. Bringing America back depends on it.

Respectfully,

Joseph Urso
CEO
ActivePure Technologies
JosephUrso@ActivePure.com

Image by Ricardo Gomez Angel

OUR SERVICES

PRODUCTS

Solar is an excellent investment that offers long-term savings